Practical Dermatology

12/17/2025

🌏 🔬PREVALENCE OF ADULT PRURIGO NODULARIS: In this video at the Dermatology Hub: Neuroimmune Network, James Q. Del Rosso, DO, FAOCD, discusses the clinical presentation of prurigo nodularis and how it differs from atopic dermatitis (AD).

📺 Watch here ➡️ https://ow.ly/kOWk50XJZNJ

James Q. Del Rosso, DO, FAOCD, discusses the clinical presentation of prurigo nodularis and how it differs from atopic dermatitis.

12/16/2025

🩺 📈 WHAT'S BEHIND INCREASED ADULT AD? In this update at the Dermatology Hub: Neuroimmune Network, Zoe Diana Draelos, MD, discusses potential reasons and contributing factors for the increasing prevalence of AD in adults, particularly in certain parts of the world. 🔎👩‍⚕️

📺 Watch here ➡️ https://ow.ly/uopI50XJXUe

Zoe Diana Draelos, MD, discusses potential reasons for the increasing prevalence of atopic dermatitis in adults, especially in certain parts of the...

12/15/2025

🔍 📊CLOSER LOOK AT SMOKING: A recent JAAD letter pointed out some key gaps in a long-term real-world study of for hidradenitis suppurativa (HS). From unaddressed smoking impacts to missing patient-reported outcomes, experts call for more comprehensive data to guide treatment. 👨‍⚕️📈

Read more ➡️ https://ow.ly/PGVW50XJUtz

12/11/2025

🔎📊 CAUSE FOR CONCERN? New research in JAMA Dermatology shows that many patients struggle to understand common skin cancer terms—especially “actinic” and “dysplastic nevus.” Even frequent dermatology patients scored below 75% comprehension.

Read more ➡️ https://ow.ly/PAia50XHBVH

12/10/2025

🔎👨‍⚕️IN DEPTH: How does chronic AD histopathology evolve from spongiosis-dominant lesions to lichenified, fibrotic plaques? Christopher Bunick, MD, FAAD, discusses the roles of the six major cytokines that drive atopic dermatitis pathophysiology: IL-4, IL-13, IL-31, TSLP, IL-22, and IFN-γ. 🩺

📺 Watch here ➡️ https://ow.ly/ujQ850XGiCY

Christopher Bunick, MD, FAAD, discusses the roles of the six major cytokines that drive atopic dermatitis pathophysiology: IL-4, IL-13, IL-31,...

12/09/2025

📢 📰 NEW DERMWIRE TV: This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well as a post-hoc analysis finding safety and efficacy for stapokibart in elderly adults with AD; and Excellergy executives discuss how recent research validated effector cell response inhibitor's trifunctional mechanism of action.

📺 Watch here ➡️ https://ow.ly/1h0e50XGiI4

This episode highlights new research showing ruxolitinib cream 1.5% providing itch relief and broader atopic dermatitis (AD) improvement, as well...

12/09/2025

📢 📊 🧬 PSORRO UPDATE: New data from the PSORRO trial show that oral roflumilast was linked with the suppression of key proinflammatory cytokines, as well as reduced immune cell infiltration in psoriasis.

Read more ➡️ https://ow.ly/rITQ50XFUwr

12/08/2025

💊 💯 PROMISING THERAPIES ON THE AD HORIZON: Justin Marson, MD, Chief Resident 2024-25 in the Department of Dermatology at SUNY Downstate Health Science University, previews important potential developments in the atopic dermatitis pipeline.

📺 Watch here ➡️ https://ow.ly/QP9W50XExNg

Justin Marson, MD, Chief Resident 2024-25 in the Department of Dermatology at SUNY Downstate Health Science University, previews important...

12/06/2025

🩺 👩‍⚕️ BIOLOGIC USE IN CHILDREN WITH AD: Dawn Zhang Eichenfield, MD, PhD, a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at the University of California, San Diego, School of Medicine, explains the most important factors to understand when prescribing biologics for pediatric patients with AD. 👶 ✨

📺 Watch here ➡️ https://ow.ly/vEp850XExLV

Dawn Zhang Eichenfield, MD, PhD, a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at the...

12/05/2025

👨‍⚕️☑️ MOISTURIZER BOOSTS SKIN BARRIER IN ACNE: A novel gel-matrix moisturizer designed for acne-prone skin improved barrier function and treatment tolerability in a new study.

Read more ➡️ https://ow.ly/CP1550XCPte

12/04/2025

🔎 🩺 💰IS THE PRICE RIGHT? A new randomized study embedded within the MEL-SELF trial suggests both low-cost and high-cost dermatoscopes enabled patients with a history of early-stage melanoma to effectively capture images for remote dermatologic assessment.

Read more ➡️ https://ow.ly/Rx1B50XC5tQ

12/03/2025

📢 NEW: A small proof-of-concept study indicates 80% of patients with moderate-to-severe hidradenitis suppurativa achieved HiSCR after 24 weeks on tirzepatide. Although early, the results suggest dual incretin therapy could offer a new treatment direction.

Read more ➡️ https://ow.ly/jkJj50XBAmU